{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:38:17Z","timestamp":1790789897476,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T00:00:00Z","timestamp":1549756800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["Luping Wang"],"award-info":[{"award-number":["Luping Wang"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008436","name":"Ernst und Berta Grimmke Stiftung","doi-asserted-by":"publisher","award":["Petra Larsen"],"award-info":[{"award-number":["Petra Larsen"]}],"id":[{"id":"10.13039\/501100008436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008436","name":"Ernst und Berta Grimmke Stiftung","doi-asserted-by":"publisher","award":["Tim Krohne"],"award-info":[{"award-number":["Tim Krohne"]}],"id":[{"id":"10.13039\/501100008436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR 2863\/7-2"],"award-info":[{"award-number":["KR 2863\/7-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005955","name":"Homann-Stiftung","doi-asserted-by":"publisher","award":["Tim Krohne"],"award-info":[{"award-number":["Tim Krohne"]}],"id":[{"id":"10.13039\/501100005955","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dr. Eberhard und Hilde R?diger Foundation","award":["Tim Krohne"],"award-info":[{"award-number":["Tim Krohne"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00109-019-01753-5","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T18:48:33Z","timestamp":1549738113000},"page":"523-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of novel selective NLRP3 inhibitors in human and murine retinal pigment epithelial cells"],"prefix":"10.1007","volume":"97","author":[{"given":"Luping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra P.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Roush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eicke","family":"Latz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-925X","authenticated-orcid":false,"given":"Tim U.","family":"Krohne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,10]]},"reference":[{"key":"1753_CR1","unstructured":"European Society of Retina Specialists (EURETINA) (2017) Retinal diseases in Europe: prevalence, incidence and healthcare needs. Available online at \n                    http:\/\/www.euretina.org\/downloads\/EURETINA_Retinal_Diseases.pdf\n                    \n                  . Accessed 31 Aug 2018"},{"key":"1753_CR2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728\u20131738","journal-title":"Lancet"},{"key":"1753_CR3","doi-asserted-by":"crossref","unstructured":"Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WG, Kaneko H, Fowler BJ, Bogdanovich S et al (2012) DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149:847\u2013859","DOI":"10.1016\/j.cell.2012.03.036"},{"key":"1753_CR4","doi-asserted-by":"crossref","unstructured":"Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC et al (2012) NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 18:791\u2013798","DOI":"10.1038\/nm.2717"},{"key":"1753_CR5","doi-asserted-by":"crossref","unstructured":"Tseng WA, Thein T, Kinnunen K, Lashkari K, Gregory MS, D\u2019Amore PA, Ksander BR (2013) NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 54:110\u2013120","DOI":"10.1167\/iovs.12-10655"},{"key":"1753_CR6","doi-asserted-by":"crossref","unstructured":"Cao S, Wang JC, Gao J, Wong M, To E, White VA, Cui JZ, Matsubara JA (2016) CFH Y402H polymorphism and the complement activation product C5a: effects on NF-\u03baB activation and inflammasome gene regulation. Br J Ophthalmol 100:713\u2013718","DOI":"10.1136\/bjophthalmol-2015-307213"},{"key":"1753_CR7","doi-asserted-by":"crossref","unstructured":"Ijima R, Kaneko H, Ye F, Nagasaka Y, Takayama K, Kataoka K, Kachi S, Iwase T, Terasaki H (2014) Interleukin-18 induces retinal pigment epithelium degeneration in mice. Invest Ophthalmol Vis Sci 55:6673\u20136678","DOI":"10.1167\/iovs.14-15367"},{"key":"1753_CR8","doi-asserted-by":"crossref","unstructured":"Budiene B, Liutkeviciene R, Gustiene O, Ugenskiene R, Laukaitiene D, Savukaityte A, Vilkeviciute A, Steponaviciute R, Rocyte A, Zaliuniene D (2018) The association of matrix metalloproteinases polymorphisms and interleukins in advanced age-related macular degeneration. Ophthalmic Genet 39:463\u2013472","DOI":"10.1080\/13816810.2018.1484928"},{"key":"1753_CR9","first-page":"1","volume":"10","author":"M Zhao","year":"2015","unstructured":"Zhao M, Bai Y, Xie W, Shi X, Li F, Yang F, Sun Y, Huang L, Li X (2015) Interleukin-1\u03b2 level is increased in vitreous of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). PLoS One 10:1\u201310","journal-title":"PLoS One"},{"key":"1753_CR10","doi-asserted-by":"crossref","unstructured":"Gao J, Cui JZ, To E, Cao S, Matsubara JA (2018) Evidence for the activation of pyroptotic and apoptotic pathways in RPE cells associated with NLRP3 inflammasome in the rodent eye. J Neuroinflammation 15:15","DOI":"10.1186\/s12974-018-1062-3"},{"key":"1753_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jphotobiol.2016.05.018","volume":"161","author":"C Brandstetter","year":"2016","unstructured":"Brandstetter C, Patt J, Holz FG, Krohne TU (2016) Inflammasome priming increases retinal pigment epithelial cell susceptibility to lipofuscin phototoxicity by changing the cell death mechanism from apoptosis to pyroptosis. J Photochem Photobiol B 161:177\u2013183","journal-title":"J Photochem Photobiol B"},{"key":"1753_CR12","doi-asserted-by":"publisher","first-page":"e8259","DOI":"10.15252\/emmm.201708259","volume":"10","author":"I Akhtar-Sch\u00e4fer","year":"2018","unstructured":"Akhtar-Sch\u00e4fer I, Wang L, Krohne TU, Xu H, Langmann T (2018) Modulation of three key innate immune pathways for the most common retinal degenerative diseases. EMBO Mol Med 10:e8259","journal-title":"EMBO Mol Med"},{"key":"1753_CR13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","volume":"19","author":"MT Heneka","year":"2018","unstructured":"Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19:610\u2013621","journal-title":"Nat Rev Neurosci"},{"key":"1753_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397\u2013411","journal-title":"Nat Rev Immunol"},{"key":"1753_CR15","doi-asserted-by":"crossref","unstructured":"Karmakar M, Katsnelson M, Malak HA, Greene NG, Howell SJ, Hise AG, Camilli A, Kadioglu A, Dubyak GR, Pearlman E (2018) Neutrophil IL-1 \u03b2 processing induced by pneumolysin is mediated by the NLRP3\/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J Immunol 194:1763\u20131775","DOI":"10.4049\/jimmunol.1401624"},{"key":"1753_CR16","doi-asserted-by":"crossref","unstructured":"Liu RT, Wang A, To E, Gao J, Cao S, Cui JZ, Matsubara JA (2015) Vinpocetine inhibits amyloid-beta induced activation of NF-\u03baB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells. Exp Eye Res 127:49\u201358","DOI":"10.1016\/j.exer.2014.07.003"},{"key":"1753_CR17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00109-015-1275-1","volume":"93","author":"C Brandstetter","year":"2015","unstructured":"Brandstetter C, Mohr LKM, Latz E, Holz FG, Krohne TU (2015) Light induces NLRP3 inflammasome activation in retinal pigment epithelial cells via lipofuscin-mediated photooxidative damage. J Mol Med 93:905\u2013916","journal-title":"J Mol Med"},{"key":"1753_CR18","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1167\/iovs.10-6172","volume":"52","author":"D Yang","year":"2011","unstructured":"Yang D, Elner SG, Clark AJ, Hughes BA, Petty HR, Elner VM (2011) Activation of P2X receptors induces apoptosis in human retinal pigment epithelium. Invest Opthalmol Vis Sci 52:1522\u20131530","journal-title":"Invest Opthalmol Vis Sci"},{"key":"1753_CR19","unstructured":"IFM Therapeutics (2017) Compounds and compositions for treating conditions associated with NLRP activity. World Intellectual Property Organization (WIPO), Geneva, Switzerland; publication number WO\/2017\/184624. Available online at \n                    https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2017184624\n                    \n                  . Accessed 31 Aug 2018"},{"key":"1753_CR20","doi-asserted-by":"crossref","unstructured":"Coll RC, Robertson AAB, Chae JJ, Higgins SC, Mu\u00f1oz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A et al (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 21:248\u2013255","DOI":"10.1038\/nm.3806"},{"key":"1753_CR21","unstructured":"Primiano MJ, Lefker BA, Bowman MR, Bree AG, Hubeau C, Bonin PD, Mangan M, Dower K, Monks BG, Cushing L et al (2018) Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary. Inflammation 773:2421\u20132433"},{"key":"1753_CR22","doi-asserted-by":"crossref","unstructured":"Krohne TU, Stratmann NK, Kopitz J, Holz FG (2010) Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp Eye Res 90:465\u2013471","DOI":"10.1016\/j.exer.2009.12.011"},{"key":"1753_CR23","doi-asserted-by":"crossref","unstructured":"Krohne TU, Kaemmerer E, Holz FG (2010) Lipid peroxidation products reduce lysosomal protease activities in human retinal pigment epithelial cells via two different mechanisms of action. Exp Eye Res 90:261\u2013266","DOI":"10.1016\/j.exer.2009.10.014"},{"key":"1753_CR24","doi-asserted-by":"crossref","unstructured":"Charbel Issa P, Barnard AR, Singh MS, Carter E, Jiang Z, Radu RA, Schraermeyer U, MacLaren RE (2013) Fundus autofluorescence in the Abca4 \u2212\/\u2212 mouse model of Stargardt disease\u2014correlation with accumulation of A2E, retinal function, and histology. Invest Ophthalmol Vis Sci 54:5602\u20135612","DOI":"10.1167\/iovs.13-11688"},{"key":"1753_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0092-8674(00)80602-9","volume":"98","author":"J Weng","year":"1999","unstructured":"Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis GH (1999) Insights into the function of rim protein in photoreceptors and etiology of Stargardt\u2019s disease from the phenotype in abcr knockout mice. Cell 98:13\u201323","journal-title":"Cell"},{"key":"1753_CR26","doi-asserted-by":"crossref","unstructured":"Kanneganti TD, Ozoren N, Body-Malapel M, Amer A, Park JH, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P et al (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin\/Nalp3. Nature 440:233\u2013236","DOI":"10.1038\/nature04517"},{"key":"1753_CR27","doi-asserted-by":"crossref","unstructured":"Mohr LK, Hoffmann AV, Brandstetter C, Holz FG, Krohne TU (2015) Effects of inflammasome activation on secretion of inflammatory cytokines and vascular endothelial growth factor by retinal pigment epithelial cells. Investig Opthalmol Vis Sci 56:6404","DOI":"10.1167\/iovs.15-16898"},{"key":"1753_CR28","first-page":"889","volume":"14","author":"M Dutot","year":"2008","unstructured":"Dutot M, Liang H, Pauloin T, Brignole-Baudouin F, Baudouin C, Warnet JM, Rat P (2008) Effects of toxic cellular stresses and divalent cations on the human P2X7 cell death receptor. Mol Vis 14:889\u2013897\u00a0","journal-title":"Mol Vis"},{"key":"1753_CR29","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.4049\/jimmunol.1402658","volume":"194","author":"MA Katsnelson","year":"2015","unstructured":"Katsnelson MA, Rucker LG, Russo HM, Dubyak GR (2015) K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol 194:3937\u20133952","journal-title":"J Immunol"},{"key":"1753_CR30","doi-asserted-by":"crossref","unstructured":"Guha S, Baltazar GC, Coffey EE, Tu LA, Lim JC, Beckel JM, Patel S, Eysteinsson T, Lu W, O\u2019Brien-Jenkins A et al (2013) Lysosomal alkalinization, lipid oxidation, and reduced phagosome clearance triggered by activation of the P2X7 receptor. FASEB J 27:4500\u20134509","DOI":"10.1096\/fj.13-236166"},{"key":"1753_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10753-016-0449-5","volume":"40","author":"A Nalbandian","year":"2017","unstructured":"Nalbandian A, Khan AA, Srivastava R, Llewellyn KJ, Tan B, Shukr N, Fazli Y, Kimonis VE, BenMohamed L (2017) Activation of the NLRP3 inflammasome is associated with Valosin-containing protein myopathy. Inflammation 40:21\u201341","journal-title":"Inflammation"},{"key":"1753_CR32","doi-asserted-by":"crossref","unstructured":"Ludwig-portugall I, Bartok E, Dhana E, Evers BD, Primiano MJ, Hall JP, Franklin BS, Knolle PA, Hornung V, Hartmann G et al (2016) An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int 90:525\u2013539","DOI":"10.1016\/j.kint.2016.03.035"},{"key":"1753_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","volume":"61","author":"C Dempsey","year":"2017","unstructured":"Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertson AAB, Cooper MA, O\u2019Neill LAJ, Lynch MA (2017) Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice. Brain Behav Immun 61:306\u2013316","journal-title":"Brain Behav Immun"},{"key":"1753_CR34","doi-asserted-by":"crossref","unstructured":"Zhou R, Yazdi AS, Menu P (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469:221\u2013225","DOI":"10.1038\/nature09663"},{"key":"1753_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00123","volume":"8","author":"AL Giuliani","year":"2017","unstructured":"Giuliani AL, Sarti AC, Falzoni S, Di Virgilio F (2017) The P2X7 receptor-interleukin-1 liaison. Front Pharmacol 8:1\u201310","journal-title":"Front Pharmacol"},{"key":"1753_CR36","doi-asserted-by":"crossref","unstructured":"Arulkumaran N, Unwin RJ, Tam FWK (2011) A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs 20:897\u2013915","DOI":"10.1517\/13543784.2011.578068"},{"key":"1753_CR37","doi-asserted-by":"crossref","unstructured":"Di Virgilio F, Ben DD, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47:15\u201331","DOI":"10.1016\/j.immuni.2017.06.020"},{"key":"1753_CR38","doi-asserted-by":"crossref","unstructured":"Kerur N, Hirano Y, Tarallo V, Fowler BJ, Bastos-Carvalho A, Yasuma T, Yasuma R, Kim Y, Hinton DR, Kirschning CJ et al (2013) TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy. Invest Ophthalmol Vis Sci 54:3\u20139","DOI":"10.1167\/iovs.13-12500"},{"key":"1753_CR39","doi-asserted-by":"crossref","unstructured":"Notomi S, Hisatomi T, Murakami Y, Terasaki H, Sonoda S, Asato R, Takeda A, Ikeda Y, Enaida H, Sakamoto T et al (2013) Dynamic increase in extracellular ATP accelerates photoreceptor cell apoptosis via ligation of P2RX7 in subretinal hemorrhage. PLoS One 8:e53338","DOI":"10.1371\/journal.pone.0053338"},{"key":"1753_CR40","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1016\/j.ajpath.2011.08.035","volume":"179","author":"S Notomi","year":"2011","unstructured":"Notomi S, Hisatomi T, Kanemaru T, Takeda A, Ikeda Y, Enaida H, Kroemer G, Ishibashi T (2011) Critical involvement of extracellular ATP acting on P2RX7 purinergic receptors in photoreceptor cell death. Am J Pathol 179:2798\u20132809","journal-title":"Am J Pathol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-019-01753-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-019-01753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-019-01753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,9]],"date-time":"2020-02-09T19:04:29Z","timestamp":1581275069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-019-01753-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1007\/s00109-019-01753-5","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,10]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"L. Wang, S. Schmidt, P. P. Larsen declare that they have no conflict of interest. J. H. Meyer declares support from Heidelberg Engineering. W. R. Roush is a shareholder and employee of IFM Therapeutics. E. Latz is a co-founder and consultant of IFM Therapeutics. F. G. Holz declares support from Acucela, Allergan, Bayer, Centervue, NightstarX, Novartis, Genentech\/Roche, Heidelberg Engineering, Optos, and Carl Zeiss Meditec. T. U. Krohne declares support from Alimera Sciences, Bayer, Heidelberg Engineering, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}